{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:10:32Z","timestamp":1778227832093,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although brain metastases (BM) represent an uncommon manifestation of colorectal cancer (CRC), their occurrence is associated with a markedly reduced life expectancy. Advances in systemic therapies and neuroimaging have led to a growing number of detected cases. However, data on prognostic markers and optimal management still remain limited. This dual center analysis from two major German cancer centers sought to describe clinical characteristics, treatment approaches and survival determinants in patients with CRC who developed BM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      All individuals diagnosed with CRC and subsequent BM between January 2000 and December 2024 were retrospectively identified from the tumor registries of the University Hospitals Wuerzburg and Frankfurt. Demographic, pathological and therapeutic parameters were extracted and analyzed. Overall survival following BM diagnosis was assessed using a multivariable Cox proportional hazards model with backward stepwise likelihood ratio selection (entry criterion\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05, removal\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.10). Hazard ratios (HR) and 95% confidence intervals (CI) were calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 279 patients (Wuerzburg 48.4%, Frankfurt 51.6%). The mean age at CRC diagnosis was 62.1 years and at BM diagnosis 65.1 years; 61.6% of the patients were male. The median interval between CRC diagnosis and BM detection in metachronous patients was 40.5 months, with 11.1% exhibiting synchronous BM. Liver, lung, and bone metastases were present in 50.9%, 64.2%, and 22.6% of patients, respectively. Among tested cases, KRAS mutations were found in 54.2%. Surgical resection of BM was undertaken in 36.2%, and radiotherapy in 67.0%. On multivariable analysis, Karnfosky Performance Status emerged as independent predictors of prolonged survival (HR\u2009=\u20090.98; 95% CI 0.97-1-00;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). Brain metastasis surgery showed a borderline association with improved survival (HR 0.51; 95% CI 0.26\u20131.00;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.050). Median survival from the time of BM diagnosis was 20 months (95% CI 14.140\u201325.860) in the operated group compared with 3 months (95% CI 2.089\u20133.911) in the non-operated group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with CRC who develop BM are a subgroup with heterogeneous courses of disease. In addition to KPS, surgical resection of BM was associated with improved survival. This emphasizing the benefit of local treatment in appropriately cases. Collaborative, prospective studies are required to validate these findings and to refine therapeutic strategies for this rare entity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05536-0","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:39:53Z","timestamp":1774334393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brain metastases from colorectal cancer \u2013 a retrospective dual center study"],"prefix":"10.1007","volume":"177","author":[{"given":"S.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Uttinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kostatin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Polat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Flemming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Lock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-T.","family":"Germer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wiegering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Pession","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"2","key":"5536_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E et al (2023) Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72(2):338\u2013344","journal-title":"Gut"},{"issue":"7","key":"5536_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D (2021) Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA 325(7):669\u2013685","journal-title":"JAMA"},{"issue":"1","key":"5536_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11060-025-05107-9","volume":"175","author":"M Alfonzo Horowitz","year":"2025","unstructured":"Alfonzo Horowitz M et al (2025) Incidence, demographics, and survival of patients with brain metastases from stage IV colorectal cancer: a population-based study from 2013 to 2023. J Neurooncol 175(1):123\u2013131","journal-title":"J Neurooncol"},{"issue":"1","key":"5536_CR4","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41598-025-85592-0","volume":"15","author":"C Luo","year":"2025","unstructured":"Luo C, Xiao Z, Yang W (2025) GNG2 inhibits brain metastases from colorectal cancer via PI3K\/AKT\/mTOR signaling pathway. Sci Rep 15(1):1787","journal-title":"Sci Rep"},{"issue":"7","key":"5536_CR5","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s11864-022-00982-0","volume":"23","author":"RB Mjahed","year":"2022","unstructured":"Mjahed RB et al (2022) Where Are We Now and Where Might We Be Headed in Understanding and Managing Brain Metastases in Colorectal Cancer Patients? Curr Treat Options Oncol 23(7):980\u20131000","journal-title":"Curr Treat Options Oncol"},{"key":"5536_CR6","doi-asserted-by":"crossref","unstructured":"M\u00fcller S et al (2021) Brain Metastases from Colorectal Cancer: A Systematic Review of the Literature and Meta-Analysis to Establish a Guideline for Daily Treatment. Cancers (Basel), 13(4)","DOI":"10.3390\/cancers13040900"},{"issue":"8","key":"5536_CR7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10147-023-02352-8","volume":"28","author":"J Imaizumi","year":"2023","unstructured":"Imaizumi J et al (2023) Prognostic factors associated with the transition in treatment methods for brain metastases from colorectal cancer. Int J Clin Oncol 28(8):1043\u20131053","journal-title":"Int J Clin Oncol"},{"key":"5536_CR8","unstructured":"Institut RK (2025) Krebs in Deutschland 2021\u20132023"},{"issue":"4","key":"5536_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.20892\/j.issn.2095-3941.2017.0068","volume":"14","author":"G Tapia Rico","year":"2017","unstructured":"Tapia Rico G et al (2017) Brain metastasis in advanced colorectal cancer: results from the South Australian metastatic colorectal cancer (SAmCRC) registry. Cancer Biol Med 14(4):371\u2013376","journal-title":"Cancer Biol Med"},{"issue":"1","key":"5536_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-024-04905-x","volume":"172","author":"V Randrian","year":"2025","unstructured":"Randrian V et al (2025) The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factors. J Neurooncol 172(1):229\u2013238","journal-title":"J Neurooncol"},{"key":"5536_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.12.005","volume":"162","author":"A Steindl","year":"2022","unstructured":"Steindl A et al (2022) Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years. Eur J Cancer 162:170\u2013181","journal-title":"Eur J Cancer"},{"issue":"1","key":"5536_CR12","doi-asserted-by":"publisher","first-page":"38887","DOI":"10.1038\/s41598-025-22760-2","volume":"15","author":"J Imaizumi","year":"2025","unstructured":"Imaizumi J et al (2025) Development and validation of a prognostic nomogram for survival in patients with brain metastases from colorectal cancer. Sci Rep 15(1):38887","journal-title":"Sci Rep"},{"issue":"1","key":"5536_CR13","doi-asserted-by":"publisher","first-page":"18574","DOI":"10.1038\/s41598-023-45939-x","volume":"13","author":"LB Callesen","year":"2023","unstructured":"Callesen LB et al (2023) Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group. Sci Rep 13(1):18574","journal-title":"Sci Rep"},{"issue":"8","key":"5536_CR14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/s41416-023-02569-4","volume":"130","author":"AA Prete","year":"2024","unstructured":"Prete AA et al (2024) HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study. Br J Cancer 130(8):1316\u20131323","journal-title":"Br J Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05536-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05536-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05536-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:16:05Z","timestamp":1778224565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05536-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5536"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05536-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}